Atrás
Precio NervGen Pharma Corp (NGENF)
Gráfico del Precio de Acciones NGENF
NGENF Ganando
NervGen Pharma Corp
$5.63
2.92%
$0.16
Al cierre: Jan 16, 16:00:00 GMT-5
$5.63
0%
$0
Mercado Posterior: Jan 16, 20:00:00 GMT-5
Estadísticas clave
Cierre Anterior
$5.47
Precio de apertura
$5.3
Rango del día
$5.3 - $5.81
Rango de 52 semanas
$1.5 - $6.3
Volumen
27.4K
Volumen promedio
143.6K
EPS (TTM)
-0.26
Rendimiento de dividendos
--
Cap. de mercado
$445.9M
¿Qué es NGENF?
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Características
Estrategias de Trading
© 2025 Finture Development Limited. All rights reserved